Patent ID: 9193789
Filing Date: 2015-11-24
Classification: A61K,A61P,C07K

Abstract:
1. An isolated human anti-ICOS antibody comprising a VH domain of an amino acid sequence of SEQ ID NO: 7, a VK domain of an amino acid sequence of SEQ ID NO: 2, and an engineered IgG1 Fc region, wherein the engineered IgG1 Fc region comprises complex N-glycoside-linked sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end of the sugar chain, wherein the antibody mediates enhanced ADCC activity as compared to the level of ADCC activity mediated by a parent antibody comprising the same VH and VK domains and a wild type Fc region, wherein said antibody depletes circulating ICOS-expressing T cells in vivo in a mammal for at least 14 days when administered as a single dose of 125 mg/m 2 .